Bio Pharma Dive
AUGUST 18, 2020
Approval of BioMarin's Roctavian, should it come as expected this week, would deliver on decades of unfulfilled hopes for a gene therapy fix to one of the earliest identified inherited diseases.
Pharma Mirror
AUGUST 17, 2020
When you many patients think of a doctor’s office, hospital, or healthcare facility, they picture a stuffy, cold, and outdated facility that increases your anxiety. Offices with old decor prevent patients from visiting the doctor regularly and feeling relaxed. But what if there was a way to modernize the office affordably to make it more. The post 5 Ways That Digital Signage Improves a Doctor’s Office appeared first on Pharma Mirror Magazine.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
World of DTC Marketing
AUGUST 21, 2020
As the NY Times recently reported , obesity is the leading cause of mortality in the United States. Obesity costs the nation $1.72 trillion every year. In the United States, where at least 4.6 million people have been infected and over 165,000 have died, the promise of a vaccine is hampered by a vexing epidemic that long preceded Covid-19: obesity.
Pharma Times
AUGUST 20, 2020
The Phase III study is evaluating the safety, tolerability and immunogenicity of GSK’s MenABCWY vaccine candidate compared to Bexsero and Menveo
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Bio Pharma Dive
AUGUST 19, 2020
BioMarin's hemophilia gene therapy Roctavian and Gilead's arthritis drug filgotinib were widely expected to win approvals from the FDA, which demanded more study data from both drugmakers.
BioPharma Reporter
AUGUST 17, 2020
Dynavax gets Bill & Melinda Gates Foundation funding to scale up production of adjuvant for use in COVID-19 vaccines.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
NY Times
AUGUST 19, 2020
Government health leaders including Dr. Francis S. Collins and Dr. Anthony S. Fauci urged caution last week, citing weak data from the country’s largest plasma study.
Bio Pharma Dive
AUGUST 20, 2020
Kesimpta, a new multiple sclerosis drug from Novartis, works the same way as Roche's blockbuster Ocrevus, but patients can take it without leaving home.
BioSpace
AUGUST 17, 2020
The new research hub will be called the London Discovery Research Centre and is expected to open by 2025.
World of DTC Marketing
AUGUST 16, 2020
Here is a copy of a talk I recently gave via Zoom to my European colleagues. Those of you who know me know that I am a frequent contributor to Hedley Rees books as well as the author of a blog that gets close to 100,000 reads a month. I have been and continue to be critical of the pharma industry but it’s not out of spite or hate. I am critical because I love this industry.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Pharma Times
AUGUST 20, 2020
Melanoma incidence rates have more than doubled in the UK
Bio Pharma Dive
AUGUST 20, 2020
The FDA's decision not to approve Roctavian raises the question of why BioMarin was able to submit the hemophilia A therapy in the first place.
BioSpace
AUGUST 19, 2020
Researchers from the Salk Institute took a major step forward in developing a new insulin-producing pancreatic cell cluster as a potential treatment for type 1 diabetes patients.
pharmaphorum
AUGUST 21, 2020
An app developed by Kaia Health to help people suffering from back pain who may not want to take painkillers has shown its worth again in a study conducted with a health benefit plan in the US. The pilot study of the app – which combines physical therapy, relaxation exercises and medical information to help back pain sufferers manage their condition – showed it was able to reduce self-reported pain and sleep quality.
Pharma Times
AUGUST 20, 2020
Findings also show increased trust in pharma and healthcare
Bio Pharma Dive
AUGUST 18, 2020
A $145 million payment to broaden a partnership with Tango Therapeutics is the latest in a series of deals Gilead has made to grow its oncology business.
BioSpace
AUGUST 19, 2020
The study concludes that they can detect almost 50% of COVID-19 cases a day before enrollees in the study reported the onset of symptoms, and they do so with 70% specificity.
pharmaphorum
AUGUST 18, 2020
Pharma companies have improved how they engage with healthcare providers as a result of COVID-19, according to a new survey of HCPs. This has resulted in pharma companies being more relevant and providing more value in closing the care gap, the report says. The Accenture survey of 720 general practitioners, oncologists, cardiologists and immunologists globally found that this is in turn helping HCPs better serve patients.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Pharma Times
AUGUST 19, 2020
Plans have been announced to test 150,000 people per fortnight across the UK from October
Bio Pharma Dive
AUGUST 20, 2020
The companies' second experimental shot caused less fever, without compromising potency, when compared to an earlier version, according to preliminary data.
BioSpace
AUGUST 16, 2020
The 11-person team at Codagenix may be tiny, but it has big plans for the company’s new COVID-19 vaccine.
Pharma Mirror
AUGUST 19, 2020
Edinburgh-based biotech company Ingenza Ltd. has made a significant breakthrough in the race to develop and manufacture a cost-effective vaccine against SARS-CoV-2, the virus responsible for the current COVID-19 pandemic. Ingenza has been working closely with researchers at Oxford University and the UK CPI, Wilton, since the start of the outbreak, and the collaboration is.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
pharmaphorum
AUGUST 16, 2020
Swittons , a P360 company, has announced a new line of Internet of Things (IoT) enabled smart devices built specifically for pharmaceutical labs. The fully customizable devices align with strategic Lab of the Future (LoTF) initiatives and help automate various laboratory workflows between people and existing digital lab equipment, systems and solutions.
Bio Pharma Dive
AUGUST 18, 2020
The Indianapolis pharma paid $200 million to gain most of the rights to Tyvyt, a checkpoint blocker that could help it compete with Merck, Roche and others.
BioSpace
AUGUST 20, 2020
The U.S. Food and Drug Administration (FDA) approved Novartis’ Kesimpta (ofatumumab) for relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Pharma Times
AUGUST 20, 2020
The treatment, developed by UCL clinicians, allows for surgery and radiation therapy at the same time
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
pharmaphorum
AUGUST 17, 2020
Sanofi is to buy Principia Biopharma for up to $3.68 billion, adding a potential multiple sclerosis drug to its pipeline. The French pharma said it will pay $100 per share in cash for San Francisco-based Principia, which specialises in Bruton’s kinase (BTK) inhibitor drugs, after the deal was unanimously agreed by both boards of directors. Sanofi’s acquisition builds on a partnership to develop central nervous system drugs that began in late 2017.
Bio Pharma Dive
AUGUST 18, 2020
Important considerations for biotech companies in early-stage development.
BioSpace
AUGUST 18, 2020
Regeneron will distribute REGN-COV-2 in the U.S. and Roche will handle distribution outside the U.S.
Pharma Times
AUGUST 20, 2020
The approval broadens the drug's label to include fifth treatment option in the relapsed/refractory multiple myeloma setting
Expert insights. Personalized for you.
363 
Let's personalize your content